GlaxoSmithKline is kicking off a large-scale Phase III trial of Syncria, an experimental diabetes drug that belongs to a class of treatments known as GLP-1 agonists. The drug is expected to compete with other incretin mimetics under development, including Novo Nordisk's liraglutide and Roche Holding's taspoglutide.

Full Story:

Related Summaries